Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BMS-986449 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Dose Escalation: BMS-986449 monotherapy | EXPERIMENTAL | - |
| Dose Escalation: BMS-986449 + nivolumab | EXPERIMENTAL | - |
| Dose Escalation: BMS-986449 monotherapy pharmacodynamic (PD) cohorts | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BMS-986449 | DRUG | Specified dose on specified days |
| Nivolumab | DRUG | Specified dose on specified days |
Inclusion Criteria: * All participants must have a histologically or cytologically confirmed, advanced, unresectable/metastatic, solid malignancy (measurable by Response Evaluation Criteria in Solid Tumors \[RECIST\] v1.1), and have received, be refractory to, ineligible for, or intolerant of exist...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 3 | PHASE2 | Pembrolizumab, Gardasil 9 |
| Incyte Corporation | INCY | 1 | PHASE2 | Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115 |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | Aldesleukin |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
BMS-986449 is an investigational small molecule being studied for the treatment of advanced solid tumors. It is in Phase 1 clinical development and is not approved for any indication. The trial enrolls adults with advanced solid tumors and includes a biomarker-selected patient population.
BMS-986449 is being developed by Bristol-Myers Squibb Company, which trades on the New York Stock Exchange under the ticker BMY. The company is the sponsor of the Phase 1 study evaluating the compound in advanced solid tumors.
BMS-986449 is in Phase 1 clinical development. It is an investigational agent and has not been approved by the FDA or any other regulatory authority. One Phase 1 trial is currently active, with no completed trials reported to date.
BMS-986449 is being evaluated in a single Phase 1 trial, NCT05888831, titled A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors. The study is active but not recruiting, plans to enroll 100 participants, and is running in the United States, Belgium, France, Italy, the Netherlands, and Spain.
The Phase 1 study NCT05888831 is a controlled trial evaluating BMS-986449 both with and without nivolumab in adults with advanced solid tumors. It is not randomized and not double blinded, enrolls participants aged 18 years and older regardless of sex, and does not include healthy volunteers.